^
    9ms
    A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (clinicaltrials.gov)
    P1, N=65, Terminated, Pfizer | Trial completion date: Nov 2023 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Mar 2024; Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • tinlorafenib (PF-07284890) • midazolam hydrochloride
    almost2years
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Trial completion date: Dec 2027 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Jan 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    almost2years
    A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=138 --> 56 | Trial completion date: Oct 2024 --> Nov 2023 | Trial primary completion date: Oct 2024 --> Nov 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • tinlorafenib (PF-07284890) • midazolam hydrochloride
    almost2years
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    2years
    A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (clinicaltrials.gov)
    P1, N=138, Recruiting, Pfizer | N=225 --> 138 | Trial completion date: Sep 2023 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Oct 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • tinlorafenib (PF-07284890) • midazolam hydrochloride
    2years
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Pfizer | Trial primary completion date: May 2026 --> Aug 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over2years
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    almost4years
    [VIRTUAL] Nonclinical development of PF-07284890 (ARRY-461), a potent, brain-penetrant, small molecule inhibitor of BRAF V600-mutation-driven tumors in vitro and in vivo (AACR 2021)
    GLP safety studies demonstrated a good safety profile for PF-07284890. PF‑07284890 is fully brain penetrant, with the potential to address this key unmet medical need and thereby defines a new class of brain penetrant, potent and selective BRAF inhibitors.
    Preclinical
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K
    |
    tinlorafenib (PF-07284890)
    almost4years
    A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (clinicaltrials.gov)
    P1, N=225, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Sep 2023 | Initiation date: Sep 2020 --> Jan 2021 | Trial primary completion date: May 2023 --> Sep 2023
    Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • tinlorafenib (PF-07284890) • midazolam hydrochloride